BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 18057866)

  • 1. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
    Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anagrelide: what was new in 2004 and 2005?
    Petrides PE
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When and how to treat essential thrombocythemia.
    Barbui T; Finazzi G
    N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
    [No Abstract]   [Full Text] [Related]  

  • 5. [Essential thrombocythemia: therapy with anagrelide].
    Mazzucconi MG; Ferrari A; Balduini CL
    Haematologica; 1991 Jun; 76 Suppl 3():378-81. PubMed ID: 1661268
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.
    Cacciola RR; Cipolla A; Di Francesco E; Giustolisi R; Cacciola E
    Am J Hematol; 2005 Sep; 80(1):81-3. PubMed ID: 16138352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of essential thrombocythemia in childhood.
    Scherer S; Ferrari R; Rister M
    Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Primary thrombocythemia: diagnosis and therapy].
    Petrides PE
    Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia.
    Cacciola RR; Francesco ED; Giustolisi R; Cacciola E
    Br J Haematol; 2004 Sep; 126(6):885-6. PubMed ID: 15352995
    [No Abstract]   [Full Text] [Related]  

  • 11. [Anagrelide in the treatment of thrombocythemia essential (ET)].
    Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
    Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin in essential thrombocythemia: status quo and quo vadis.
    Griesshammer M; Bangerter M; van Vliet HH; Michiels JJ
    Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
    Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
    Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
    Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
    Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
    Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
    Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of delirium associated with essential thrombocythemia by antiplatelet therapy.
    Campbell KM; Schubert DS
    Psychosomatics; 1992; 33(2):213-5. PubMed ID: 1557486
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of essential thrombocythemia].
    Alvarez-Larrán A; Cervantes F; Besses C
    Med Clin (Barc); 2013 Sep; 141(6):260-4. PubMed ID: 23490491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indications for lowering platelet numbers in essential thrombocythemia.
    Barbui T
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.